|
1
|
Vaccarella S, Franceschi S, Engholm G,
Lönnberg S, Khan S and Bray F: 50 years of screening in the Nordic
countries: Quantifying the effects on cervical cancer incidence. Br
J Cancer. 111:965–969. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pfaendler KS and Tewari KS: Changing
paradigms in the systemic treatment of advanced cervical cancer. Am
J Obstet Gynecol. 214:22–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ronco G, Dillner J, Elfström KM, Tunesi S,
Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi
P, et al: International HPV screening working group: Efficacy of
HPV-based screening for prevention of invasive cervical cancer:
Follow-up of four European randomised controlled trials. Lancet.
383:524–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lo Faro ML, Fox B, Whatmore JL, Winyard PG
and Whiteman M: Hydrogen sulfide and nitric oxide interactions in
inflammation. Nitric Oxide. 41:38–47. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bogdan C: Nitric oxide synthase in innate
and adaptive immunity: An update. Trends Immunol. 36:161–178. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
King AL, Polhemus DJ, Bhushan S, Otsuka H,
Kondo K, Nicholson CK, Bradley JM, Islam KN, Calvert JW, Tao YX, et
al: Hydrogen sulfide cytoprotective signaling is endothelial nitric
oxide synthase-nitric oxide dependent. Proc Natl Acad Sci USA.
111:3182–3187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marigo I, Zilio S, Desantis G, Mlecnik B,
Agnellini AHR, Ugel S, Sasso MS, Qualls JE, Kratochvill F,
Zanovello P, et al: T cell cancer therapy requires CD40-CD40L
activation of tumor necrosis factor and inducible
nitric-oxide-synthase-producing dendritic cells. Cancer Cell.
30:377–390. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo FQ and Crawford NM: Arabidopsis nitric
oxide synthase1 is targeted to mitochondria and protects against
oxidative damage and dark-induced senescence. Plant Cell.
17:3436–3450. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ambs S, Merriam WG, Bennett WP,
Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG,
Billiar TR and Harris CC: Frequent nitric oxide synthase-2
expression in human colon adenomas: Implication for tumor
angiogenesis and colon cancer progression. Cancer Res. 58:334–341.
1998.PubMed/NCBI
|
|
10
|
Xu W, Liu LZ, Loizidou M, Ahmed M and
Charles IG: The role of nitric oxide in cancer. Cell Res.
12:311–320. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang F, Xue X, Wei J, An Y, Yao J, Cai H,
Wu J, Dai C, Qian Z, Xu Z, et al: hsa-miR-520h downregulates ABCG2
in pancreatic cancer cells to inhibit migration, invasion, and side
populations. Br J Cancer. 103:567–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang Y, He Y, Li H, Li HN, Zhang L, Hu W,
Sun YM, Chen FL and Jin XM: Expressions of putative cancer stem
cell markers ABCB1, ABCG2, and CD133 are correlated with the degree
of differentiation of gastric cancer. Gastric Cancer. 15:440–450.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fionda C, Abruzzese MP, Zingoni A, Soriani
A, Ricci B, Molfetta R, Paolini R, Santoni A and Cippitelli M:
Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in
multiple myeloma cells: Role of DNA damage response activation. BMC
Cancer. 15:172015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fahey JM and Girotti AW: Accelerated
migration and invasion of prostate cancer cells after a
photodynamic therapy-like challenge: Role of nitric oxide. Nitric
Oxide. 49:47–55. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Puglisi MA, Cenciarelli C, Tesori V,
Cappellari M, Martini M, Di Francesco AM, Giorda E, Carsetti R,
Ricci-Vitiani L and Gasbarrini A: High nitric oxide production,
secondary to inducible nitric oxide synthase expression, is
essential for regulation of the tumour-initiating properties of
colon cancer stem cells. J Pathol. 236:479–490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Chandrashekar K, Wang L, Lai EY,
Wei J, Zhang G, Wang S, Zhang J, Juncos LA and Liu R: Inhibition of
nitric oxide synthase 1 induces salt-sensitive hypertension in
nitric oxide synthase 1α knockout and wild-type mice. Hypertension.
67:792–799. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rabender CS, Alam A, Sundaresan G,
Cardnell RJ, Yakovlev VA, Mukhopadhyay ND, Graves P, Zweit J and
Mikkelsen RB: The role of nitric oxide synthase uncoupling in tumor
progression. Mol Cancer Res. 13:1034–1043. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang J, He P, Gaida M, Yang S, Schetter
AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis H, Lee D, et al:
Inducible nitric oxide synthase enhances disease aggressiveness in
pancreatic cancer. Oncotarget. 7:52993–53004. 2016.PubMed/NCBI
|
|
20
|
Wang J, Yang S, He P, Schetter AJ, Gaedcke
J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, et al:
Endothelial nitric oxide synthase traffic inducer (NOSTRIN) is a
negative regulator of disease aggressiveness in pancreatic cancer.
Clin Cancer Res. 22:5992–6001. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Basudhar D, Somasundaram V, de Oliveira
GA, Kesarwala A, Heinecke JL, Cheng RY, Glynn SA, Ambs S, Wink DA
and Ridnour LA: Nitric oxide synthase-2-derived nitric oxide drives
multiple pathways of breast cancer progression. Antioxid Redox
Signal. 26:1044–1058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang Y, Hou J, Li G, Song Z, Li X, Yang C,
Liu W, Hu Y and Xu Y: ABCG2 regulates the pattern of self-renewing
divisions in cisplatin-resistant non-small cell lung cancer cell
lines. Oncol Rep. 32:2168–2174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Noguchi K, Katayama K and Sugimoto Y:
Human ABC transporter ABCG2/BCRP expression in chemoresistance:
Basic and clinical perspectives for molecular cancer therapeutics.
Pharm Genomics Pers Med. 7:53–64. 2014.
|
|
24
|
Lagas JS, van Waterschoot RA, Sparidans
RW, Wagenaar E, Beijnen JH and Schinkel AH: Breast cancer
resistance protein and P-glycoprotein limit sorafenib brain
accumulation. Mol Cancer Ther. 9:319–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
